Skip to content
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Radiology · Ductal Carcinoma In Situ

How Common Is DCIS, and Can Men Develop It? Key Facts

At a Glance

DCIS is common among breast cancers found in women through mammography, but it is very rare in men. It stays inside the milk ducts, though some cases can become invasive, so biopsy results and individual risk factors guide treatment and genetic counseling.

Ductal carcinoma in situ (DCIS) is noninvasive, meaning the abnormal cells are confined to the milk ducts and cannot spread to other parts of the body unless an invasive component develops or was missed during biopsy. The prognosis is generally excellent, but because of its potential to become invasive over time, it requires careful evaluation.

DCIS is frequently found during breast imaging in women. It accounts for roughly 15% to 25% of all newly diagnosed breast cancers in the United States [1][2]. Men can also develop DCIS, but it is exceptionally rare; pure DCIS accounts for only about 5% to 10% of all male breast cancer cases [3][4].

In U.S. data, such as the SEER registry from 2000 to 2014, the average age at the time of a DCIS diagnosis was typically in the mid-to-late 50s [5][6]. While overall rates of diagnosis remained broadly stable during that period, there was a slight annual increase in diagnoses among younger women between the ages of 20 and 55 [6].

The Impact of Mammography Screening

The high number of DCIS cases diagnosed today is primarily the result of widespread mammography screening [7]. Mammograms are highly effective at spotting microcalcifications—tiny deposits of calcium in the breast tissue [8]. It is important to know that many calcifications are completely benign (harmless), but they can indicate an area that needs additional imaging and a biopsy. A mammogram cannot diagnose DCIS; only a biopsy examined by a pathologist can confirm the diagnosis.

Because modern screening catches so many early lesions, experts acknowledge that some cases of DCIS represent overdiagnosis [9]. Overdiagnosis means that a detected DCIS would never have grown, spread, or caused symptoms during the person’s natural lifetime [10]. However, doctors currently cannot predict with absolute certainty which individual cases of DCIS will remain harmless and which will progress to invasive cancer [9].

While most medical guidelines favor definitive treatment (such as surgery, sometimes followed by radiation or hormone-blocking therapy) to reduce the risk of a future invasive recurrence, management is highly individualized [10][11]. Doctors look at features like tumor grade (how abnormal the cells look) and hormone receptor status (whether the cells grow in response to estrogen or progesterone) to guide care [12][11]. For some selected patients with low-risk features, active surveillance (careful monitoring) may be discussed, often as part of a clinical trial [10].

Racial and Ethnic Patterns

When looking at populations, diagnosis rates and outcomes can vary. Over recent decades, U.S. registry data showed increasing DCIS diagnoses among Black, Hispanic, and Asian/Pacific Islander women [13]. However, when researchers adjusted the data to account for differences in mammography screening rates, the underlying incidence of DCIS was very similar between Black and White women [13].

Despite similar underlying rates, disparities exist in disease outcomes. Some data indicate that Black women may face a higher risk of DCIS returning as an invasive cancer or have a higher breast cancer-specific mortality rate compared to White women [14][15]. These differences are complex and are influenced by healthcare access, treatment delays, socioeconomic factors, and tumor biology [16][11].

DCIS in Men and Genetic Risk

Men have a small amount of breast tissue containing milk ducts, meaning they can develop DCIS [3]. American Society of Clinical Oncology (ASCO) guidelines state that genetic counseling and inherited (germline) genetic testing should be offered to all men diagnosed with breast cancer, including DCIS, regardless of their age or family history [17][18].

Genetic evaluation is particularly crucial if a man has a family history of:

  • Male breast cancer [19]
  • Female breast cancer diagnosed before age 50 [20]
  • Ovarian, pancreatic, or aggressive prostate cancer [20][21]

Testing usually involves a multigene panel (testing multiple genes at once, such as BRCA1, BRCA2, PALB2, and CHEK2) [22][23]. It is important to know that a genetic test can be negative, and a DCIS diagnosis does not mean a genetic mutation is inevitable. Sometimes tests reveal a “variant of uncertain significance,” which should not be used to guide preventive care [17].

However, if a clinically significant mutation is found, it can help guide the patient’s own future screenings (like for prostate or pancreatic cancer, depending on the exact gene involved) [24]. It also allows blood relatives to receive cascade testing (targeted testing for that specific family mutation) after they undergo their own genetic counseling [17].

Common questions in this guide

How common is ductal carcinoma in situ?
DCIS accounts for roughly 15% to 25% of newly diagnosed breast cancers in the United States. Its frequent detection is largely linked to mammography screening, which can find early changes before symptoms develop.
Can men develop DCIS?
Yes. Men have a small amount of breast tissue containing milk ducts, so they can develop DCIS, but it is exceptionally rare. Pure DCIS makes up only about 5% to 10% of male breast cancer cases.
How is DCIS confirmed after a mammogram?
A mammogram may show microcalcifications, but it cannot confirm DCIS by itself. A biopsy must be examined by a pathologist to determine whether abnormal cells are confined to the milk ducts.
Does a DCIS diagnosis mean the cancer is invasive?
No. DCIS is noninvasive because the abnormal cells remain inside the milk ducts, and the prognosis is generally excellent. Some DCIS can become invasive over time, but doctors cannot reliably predict which individual cases will progress.
Should a man with DCIS have genetic testing?
American Society of Clinical Oncology guidelines recommend genetic counseling and inherited genetic testing for all men diagnosed with breast cancer, including DCIS, regardless of age or family history. A multigene panel may identify an inherited mutation that affects future screening and provides useful information for blood relatives.
Can DCIS be overdiagnosed?
Yes. Screening may find some DCIS that would never have grown, spread, or caused symptoms during a person’s lifetime. Because doctors cannot identify every harmless case with certainty, treatment or carefully monitored surveillance is considered based on the individual’s risk features.

Get notified when new evidence is published on ductal breast carcinoma in situ.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (24)
  1. 1

    Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment.

    Delaloge S, Khan SA, Wesseling J, Whelan T

    Lancet (London, England) 2024; (403(10445)):2734-2746 doi:10.1016/S0140-6736(24)00425-2.

    PMID: 38735296
  2. 2

    Intratumoral Heterogeneity in Ductal Carcinoma In Situ: Chaos and Consequence.

    Sinha VC, Piwnica-Worms H

    Journal of mammary gland biology and neoplasia 2018; (23(4)):191-205 doi:10.1007/s10911-018-9410-6.

    PMID: 30194658
  3. 3

    Male ductal carcinoma in situ: diagnosis and management of a rare disease in men.

    Tian C, Alvarado R, Kim T, Slostad J

    BMJ case reports 2024; (17(3)) doi:10.1136/bcr-2023-256608.

    PMID: 38499353
  4. 4

    Mammographically and sonographically occult male DCIS seen only on breast MRI.

    Osei K, Panigrahi B

    Radiology case reports 2024; (19(8)):3390-3393 doi:10.1016/j.radcr.2024.05.006.

    PMID: 38841603
  5. 5

    Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.

    Narod SA, Iqbal J, Giannakeas V, et al.

    JAMA oncology 2015; (1(7)):888-96 doi:10.1001/jamaoncol.2015.2510.

    PMID: 26291673
  6. 6

    Incidence of Ductal Carcinoma In Situ in the United States, 2000-2014.

    Ryser MD, Hendrix LH, Worni M, et al.

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2019; (28(8)):1316-1323 doi:10.1158/1055-9965.EPI-18-1262.

    PMID: 31186262
  7. 7

    The contribution of mammography screening to breast cancer incidence trends in the United States: an updated age-period-cohort model.

    Gangnon RE, Sprague BL, Stout NK, et al.

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2015; (24(6)):905-12 doi:10.1158/1055-9965.EPI-14-1286.

    PMID: 25787716
  8. 8

    Recall and Outcome of Screen-detected Microcalcifications during 2 Decades of Mammography Screening in the Netherlands National Breast Screening Program.

    Luiten JD, Voogd AC, Luiten EJT, et al.

    Radiology 2020; (294(3)):528-537 doi:10.1148/radiol.2020191266.

    PMID: 31990268
  9. 9

    Overdiagnosis of ductal carcinoma in situ by grade and definition in population-based screening: A modeling study.

    Poelhekken K, Greuter MJW, van der Vegt B, et al.

    Breast (Edinburgh, Scotland) 2025; (84()):104594 doi:10.1016/j.breast.2025.104594.

    PMID: 41082841
  10. 10

    Modeling Ductal Carcinoma In Situ (DCIS): An Overview of CISNET Model Approaches.

    van Ravesteyn NT, van den Broek JJ, Li X, et al.

    Medical decision making : an international journal of the Society for Medical Decision Making 2018; (38(1_suppl)):126S-139S doi:10.1177/0272989X17729358.

    PMID: 29554463
  11. 11

    Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial.

    Kantor O, King TA, Jones A, et al.

    Annals of surgical oncology 2023; (30(13)):8404-8411 doi:10.1245/s10434-023-14344-z.

    PMID: 37777685
  12. 12

    Racial Disparity in Ductal Carcinoma in Situ: Risk-Predictive and Actionable Biomarkers for Early Intervention.

    Franklin D, Rida P, Jinna N

    Cancers 2026; (18(11)) doi:10.3390/cancers18111794.

    PMID: 42279376
  13. 13

    Twenty-Five Year Trends in the Incidence of Ductal Carcinoma in Situ in US Women.

    Oseni TO, Zhang B, Coopey SB, et al.

    Journal of the American College of Surgeons 2019; (228(6)):932-939 doi:10.1016/j.jamcollsurg.2019.01.018.

    PMID: 30772444
  14. 14

    Race-related subsequent breast events after ductal carcinoma in situ: A Surveillance, Epidemiology, and End Results-based analysis.

    Koric A, Jiang S, Liu Y, Colditz GA

    Cancer 2025; (131(22)):e70164 doi:10.1002/cncr.70164.

    PMID: 41199479
  15. 15

    Trends in breast cancer death rates from ductal carcinoma in situ versus invasive cancer in the United States.

    Sung H, Jiang C, Jatoi I, Jemal A

    Breast cancer research : BCR 2025; (27(1)):164 doi:10.1186/s13058-025-02068-9.

    PMID: 41013593
  16. 16

    Racial/ethnic differences in tumor biology and treatment outcomes in women with ductal carcinoma in situ.

    Black DM, Day CN, Piltin MA, et al.

    Surgery 2025; (179()):108940 doi:10.1016/j.surg.2024.08.059.

    PMID: 39603875
  17. 17

    Management of Male Breast Cancer: ASCO Guideline.

    Hassett MJ, Somerfield MR, Baker ER, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(16)):1849-1863 doi:10.1200/JCO.19.03120.

    PMID: 32058842
  18. 18

    Multigene Germline Testing in Patients with DCIS vs Invasive Breast Cancer in a Large, Integrated Health Care System.

    Dzubnar JM, Habel LA, Jiang SF, et al.

    Annals of surgical oncology 2026; (33(5)):4436-4442 doi:10.1245/s10434-025-19053-3.

    PMID: 41530599
  19. 19

    Family history of breast cancer in men with non-BRCA male breast cancer: implications for cancer risk counseling.

    Calip GS, Kidd J, Bernhisel R, et al.

    Breast cancer research and treatment 2021; (185(1)):195-204 doi:10.1007/s10549-020-05922-w.

    PMID: 32918117
  20. 20

    Protocol to evaluate sequential electronic health record-based strategies to increase genetic testing for breast and ovarian cancer risk across diverse patient populations in gynecology practices.

    Symecko H, Schnoll R, Beidas RS, et al.

    Implementation science : IS 2023; (18(1)):57 doi:10.1186/s13012-023-01308-w.

    PMID: 37932730
  21. 21

    Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers.

    Clark NM, Roberts EA, Fedorenko C, et al.

    Annals of surgical oncology 2023; (30(3)):1312-1326 doi:10.1245/s10434-022-12755-y.

    PMID: 36335273
  22. 22

    Prevalence of Cancer Predisposition Germline Variants in Male Breast Cancer Patients: Results of the German Consortium for Hereditary Breast and Ovarian Cancer.

    Rolfes M, Borde J, Möllenhoff K, et al.

    Cancers 2022; (14(13)) doi:10.3390/cancers14133292.

    PMID: 35805063
  23. 23

    Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.

    Pritzlaff M, Summerour P, McFarland R, et al.

    Breast cancer research and treatment 2017; (161(3)):575-586 doi:10.1007/s10549-016-4085-4.

    PMID: 28008555
  24. 24

    Cancer risks associated with BRCA1 and BRCA2: Overview and management.

    Breen KE, Vashisth S, Liu YL

    Cancer 2026; (132(20)):e70635 doi:10.1002/cncr.70635.

    PMID: 42875977

This page is for informational purposes only and does not constitute medical advice about DCIS, male breast cancer, or genetic testing. Discuss your individual diagnosis and options with your healthcare team.